Invitation to Cereno Scientific webcast: Clinical Phase II study with drug candidate CS1 in PAH
Cereno Scientific (XSAT: CRNO B) invites investors, financial analysts, and media to a webcast presentation on February 25, 2022. The presentation will focus on the Phase II study of drug candidate CS1 in the rare disease pulmonary arterial hypertension (PAH). Chief Executive Officer, Sten R. Sörensen and Chief Medical Officer Dr. Björn Dahlöf from Cereno will be joined by Dr. Raymond Benza, Principal Investigator for the study and Dr. Philip Adamson, Vice President and Chief Medical Officer at study collaborator Abbott. The presentations will cover the background, design, and plan for the clinical trial.
This virtual event will take place on February 25 at 15:00-16:00 CET. The webcast will be livestreamed and can be accessed via the link: https://tv.streamfabriken.com/cereno-scientific-webcast-update-on-phase-2-clinical-study-2022. No pre-registration is needed. A recording of the webcast will be published on Cereno Scientific’s website after the event. All presentations will be held in English.
Presenters:
Sten R. Sörensen, Chief Executive Officer Cereno Scientific
Dr. Björn Dahlöf, Chief Medical Officer Cereno Scientific
Dr. Raymond Benza, Professor of Medicine and Director for the Division of Cardiovascular Diseases at Wexner Medical Center, Ohio State University
Dr. Philip Adamson, Divisional Vice President and Chief Medical Officer for the Heart Failure Division of Abbott
The Phase II study intends to evaluate drug candidate CS1’s safety, tolerability, dose and exploratory efficacy in patients with the rare disease PAH. The study will be executed at up to nine different US clinical sites and include 30 patients. Further information about the study is available at www.clinicaltrials.gov (ClinicalTrials.gov identifier NCT05224531).
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The CS585 program consists of stable, selective, and potent IP (prostacyclin) receptor agonists and the CS014 program comprises HDAC inhibitors with epigenetic effects. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.